Tags: Trump Administration | fda | cancer | drug | Steve Jobs

FDA Approves Drug for Rare Cancer That Killed Steve Jobs

FDA Approves Drug for Rare Cancer That Killed Steve Jobs
(Getty Images)

Friday, 26 January 2018 02:06 PM

The U.S. Food and Drug Administration on Thursday approved a therapy for a rare type of digestive tract cancer that killed Apple co-founder Steve Jobs in 2011.

The approval for the drug made by French drugmaker Advanced Accelerator Application SA comes three months after Swiss giant Novartis AG agreed to buy the company for $3.9 billion.

The treatment, Lutathera, was approved to treat a type of cancer called gastroenteropancreatic neuroendocrine tumors that affect the pancreas or gastrointestinal tract.

There are about 6.98 cases of neuroendocrine tumors for every 100,000 people in the United States each year, the company said.

Lutathera, which already has a European approval, harnesses a molecule to diagnose cancer and hits tumors with high-energy electrons. 

© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Newsfront
The U.S. Food and Drug Administration on Thursday approved a therapy for a rare type of digestive tract cancer that killed Apple co-founder Steve Jobs in 2011. The approval for the drug made by French drugmaker Advanced Accelerator Application SA comes three months after...
fda, cancer, drug, Steve Jobs
118
2018-06-26
Friday, 26 January 2018 02:06 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved